New Delhi, November 2 (agencies): Bharat Biotech, which is developing India’s indigenous coronavirus vaccine, is planning to launch the vaccine in the second quarter of 2021 if it gets the approval from regulatory authorities, a company executive told Reuters.
AIIMS Delhi is likely to submit a proposal to its ethics committee on Phase III clinical trials of Covaxin. Bharat Biotech, which has received initial approval from Drugs Controller General of India to conduct late-stage trials for its vaccine candidate Covaxin said it plans to conduct recruitment and dosage for the Phase III trials in November.
The trial will be conducted in 25 sites in 10-12 states and will provide two doses each for the vaccine and placebo recipients, the company’s Executive Director Sai Prasad said.
Meet R.N. Ravi, who is mediating peace with the Nagas
What Does Your Face Say About Your Health?
An orbiting message of peace
The last Konyak headhunters of Nagaland
Leave a Reply
Your email address will not be published. Required fields are marked (required)